The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology.

REDCAR, United Kingdom (PRWEB)
August 03, 2022

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the near doubling of its manufacturing facility in northeast England. The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows. The additional space and equipment will enable Absolute Antibody to better service customers and accelerate the expansion of its recombinant antibody portfolio.

“The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology,” said Dr. Ed Horton, Chief Commercial Officer of Absolute Antibody. “We are excited to leverage our increased production capacity and additional automation capabilities to serve new and existing customers more efficiently and respond to the growing demand for recombinant antibodies across a variety of applications.”

The facility is ISO-certified and located at the Wilton Centre in Redcar, England, where Absolute Antibody has based its research and manufacturing since 2014. The upgraded space includes additional manufacturing lines and state-of-the-art robotics to increase efficiency and enable the completion of larger and higher volume projects. The new labs will also accommodate additional scientific staff members to support company growth, while still providing the highest quality antibody services and products.

Absolute Antibody’s facility expansion follows its recent acquisition by LSBio, which provides clients with a larger portfolio of antibody-related products and services. The combined company is focused on increasing the availability of highly defined recombinant antibodies, which offer ensured reproducibility, an animal-free manufacturing process, and the ability to engineer antibodies into any species, isotype or format.

Since its founding in 2012, Absolute Antibody has grown rapidly. The company’s custom antibody sequencing, engineering and expression services are used by leading pharmaceutical, biotechnology and diagnostics companies, as well as by academic researchers worldwide. Its reagents catalog offers a wide range of recombinant antibodies in new engineered formats, absolutely defined at the amino acid level to ensure batch-to-batch reproducibility.

About Absolute Antibody, Ltd.

Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Share article on social media or email:

“Thomas Schlumpberger is an experienced and admired leader in the POC diagnostics field where he has achieved extraordinary success in every management role,” said Slone Partners President Tara Kochis.

SOUTH RIDING, Va. (PRWEB)
August 01, 2022

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Thomas Schlumpberger as Chief Executive Officer (CEO) and member of the Board of Directors at Nanomix, a leader in mobile, affordable, point-of-care (POC) diagnostics.

Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. In his most recent role, as CEO of Pictor Limited, he revamped the company’s product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. At Epocal, a POC company, he was responsible for international business and business development. Schlumpberger has also held senior executive roles with several other diagnostics companies, including Anixa, InVitae, Inivata, and Affymetrix, now part of Thermo Fisher Scientific.

“Thomas Schlumpberger is an experienced and admired leader in the POC diagnostics field where he has achieved extraordinary success in every management role,” said Slone Partners President Tara Kochis. “He will bring tremendous passion, intellect, and vision to the Nanomix leadership team.”

“We are excited to welcome Dr. Schlumpberger to the management team. His strong leadership will be invaluable as we work to establish our technology as a standard of care in point-of-care (POC) diagnostics. His breadth of experience in POC diagnostics will be instrumental as we accelerate the commercialization of the eLab system worldwide,” said Garrett Gruener, Chairman of the Nanomix Board of Directors.

“I am thrilled and excited to join Nanomix,” said Schlumpberger. “I truly believe the Nanomix eLab® system is the best POC diagnostic technology on the market today, which is why I chose to join the Nanomix management team. Nanomix’s quantitative and highly sensitive detection platform that performs a range of in vitro diagnostic assays, including but not limited to sepsis diagnosis and monitoring, has the potential to transform POC diagnostics.”

Schlumpberger received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT NANOMIX CORPORATION

Nanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit http://www.nano.com.

Share article on social media or email:

PI Ultrasonic Transducers: Miniature, Medium and Large, in Hemispherical and Spherical Designs

AUBURN, Mass. (PRWEB)
July 26, 2022

PI Ceramic, a global leader in the design and production of ultrasonic transducers, piezoelectric actuators and electro-ceramic mechanisms, offers a line of standard-size and miniaturized transducers for ultrasonic applications. Piezoelectric ultrasonic transducers can transmit and detect soundwaves up to very high frequencies in the Megahertz range. In medical applications, ultrasound is used for therapeutics, for tumors removal, for imaging, and also for blood flow monitoring. In industrial automation applications, contactless fluid metering of liquids and gases, and level detection systems are also based on ultrasound transducers. As for every-day life applications, most modern cars have piezoelectric ultrasound transducers built into their bumpers to help the drivers avoid collisions with nearby objects during parking maneuvers.

Piezo Effect and Ultrasound Generation

Piezoelectric materials convert electrical energy into mechanical energy and vice versa; the so-called inverse piezo effect is harnessed for the generation of oscillation and precision motion. For ultrasonic applications that require high bandwidth, hemispheres and hollow spheres are currently available with an outside diameter range from 2 – 100mm with wall thickness as small as 0.2mm. Uses for electro-ceramic spherical transducers include medical high-intensity focused ultrasound (HIFU), therapeutic ultrasound, hydrophones, and sonar transducers.

Types of Piezoelectric Transducers

PI Ceramic designs and manufactures standard and custom piezoelectric ultrasound transducers. Available are the following standard and custom transducer types: discs, rings, rods, plates, cylinders, tubes, hemispheres, and hollow spheres for applications including therapeutics, surgery, echolocation (sonar), precision dosing, micro and nano-dispensing, digital printing, flow measurement, and downhole communication.

To learn more on the Applications of Ultrasound Piezo Transducers, read this Blog Post.

About PI Ceramic

PI Ceramic (PIC) is part of the PI (Physik Instrumente) Group and provides piezo products for precision motion and nanopositioning applications as well as classical piezoelectric ultrasonic transducer products for industry and medical applications for both sensing and power generation. PIC continuously increases its investments in materials research, design and automation, to provide the highest performance, highest reliability piezo products to the market. PI Ceramic piezoelectric actuators were employed by NASA on the Mars Mission after they had survived lifetime tests of 100 Billion cycles. PI Ceramic was founded 30 years ago as a subsidiary of PI (Physik Instrumente) and currently employs 400 staff. Watch video webinar on Youtube: Piezoelectric Transducers for Liquid Handling, IVD, PoC, Cytometry, Array Spotting

Share article on social media or email:

This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting + Clinical Lab Expo.

SAN CARLOS, Calif. (PRWEB)
July 25, 2022

This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting + Clinical Lab Expo. The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Its annual event showcases cutting-edge research, technology and automation shaping the future of diagnostics.

More than 300 expert speakers will present at more than 250 educational sessions this year, including Clear Labs’ Director of Assay Development Prasanna Thwar, PhD, who is leading a session on Whole Genome Sequencing (WGS) and applications for tracking Hospital Acquired Infections (HAIs) to help hospitals to have better infection control in their facilities, resolve outbreak investigations in near real-time, and flag strains that have antimicrobial resistance and virulence markers.

WHEN: Thursday, July 28 from 10:00 am. – 10:20 am CT

WHAT: Isolate Whole Genome Sequencing (WGS) and Applications for Tracking Hospital Acquired Infections (HAIs)

WHO: Clear Labs Director of Assay Development Prasanna Thwar

​​

WHERE: McCormick Place Chicago

Exhibit Hall Theater 1

2301 S King Drive, Chicago, IL 60616

WHY: This session will feature a discussion on how a fully automated WGS system and sophisticated analytics can enable a clinical laboratory to easily sequence and characterize bacterial pathogens implicated in real-world HAIs to better track and trace possible sources of infection.

Clear Labs’ Dr. Thwar will also present a new scientific poster titled “Automation of isolate Whole Genome Sequencing (WGS) to empower detection and surveillance of Healthcare-associated Infections (HAI)” – Poster # B-128 at the event and the Clear Labs team will be at booth #5014. This poster was awarded first place by the 2022 AACC Industry Division in their poster competition. The Clear Dx™ fully automated next generation sequencing instrument will also be on-display in the booth and available for demos to booth visitors. For more information about Clear Labs and upcoming events, visit https://www.clearlabs.com/newsroom/.

About Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy for detection and surveillance of infectious diseases. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Share article on social media or email:

An expert team of contributors has updated the book’s content to address current challenges facing western agriculture.

“This latest edition continues to promote and emphasize the agronomically sound and environmentally safe uses of fertilizers.”

SACRAMENTO, Calif. (PRWEB)
July 18, 2022

Western Plant Health (WPH) today announced that the release date for the 10th Edition of its immensely popular Western Fertilizer Handbook will be September 7, 2022 and is now available for pre-orders here.

For almost 70 years, agronomists throughout the western United States have relied on the Western Fertilizer Handbook for the most accurate information to maintain efficient and profitable growing programs, according to WPH. This latest edition continues to promote and emphasize the agronomically sound and environmentally safe uses of fertilizers.

“Ever since we created this this handbook in the 1950s, it has served as an indispensable resource for western farmers, agronomists, crop advisors and those in academia,” said Renee Pinel, President & CEO of WPH. “There are thousands of these books in circulation and there is a large audience eager to obtain this latest edition.”

An expert team of contributors has updated the book’s content to address current challenges facing western agriculture. Additional material has been added on micro-irrigation; soil, water, and tissue analysis; remote sensing of crop nutrient and water status; and agronomic decision support software.

The handbook is intended as a way to develop a better understanding of the different agronomic principles and practices as well as the different factors related to soil, water, plants, and fertilizers. It is used in universities across the West as part of their agricultural curriculum and serves as the primary study guide for candidates taking the California Certified Crop Adviser exam.

The handbook is a “practical tool for agronomists, CCAs, and PCAs working in the West, where it can frequently be found in their pickup trucks and offices because it is such a valuable resource,” said C. Scott Stoddard, a farm advisor and PCA with the University of California Cooperative Extension. ”Additionally, it is an excellent resource and textbook for classes on soil fertility and irrigation management.“

Click here to pre-order: Western Fertilizer Handbook

371 pages, $54.95 list

ISBN 10: 1-4786-4739-6

ISBN 13: 978-1-4786-4739-3

About Western Plant Health:

Western Plant Health (WPH) is a Sacramento-based trade association whose member companies promote the environmentally safe and agronomically sound use of their products. WPH members provide farmers with a wide range of crop protection and fertilizers necessary for safely growing crops that produce nutritious food and high-quality fiber, as well as horticultural products.

Share article on social media or email:

In the field of cancer immunotherapy… investigating and understanding the metabolic activities of cells are critical.

TORONTO (PRWEB)
July 12, 2022

Among the various biological functions cells carry out to maintain life, metabolism is the key activity used to process nutrient molecules. It is also closely associated with cell proliferation and differentiation. Cell metabolic analysis would be very helpful to monitor these activities.

In the field of cancer immunotherapy — such as CAR T and TCR-T therapy, stem cell research including embryonic stem (ES) and induced pluripotent stem (iPS) cells and commercial cell and gene therapy (CGT) manufacturing process development — investigating and understanding the metabolic activities of cells are critical. To meet this need in the field, PHC Corporation will launch a continuous metabolic analyzer which leads to real-time visualization of the metabolic condition of living cells. This development will encourage new discoveries that have not been seen in previous studies.

Register for this webinar to learn how live cell metabolic analysis paves the way not only for metabolic research, but also the manufacturing of significant CGT products.

Join experts from PHC Corporation of North America, Ryosuke Takahashi, PhD VP, Cell and Gene Therapy Business; and Kenan Moss, Application Specialist, for the live webinar on Tuesday, July 26, 2022, at 11am EDT (4pm BST).

For more information, or to register for this event, visit Live Cell Metabolic Analysis — Paving the Way for Metabolic Research and Cell & Gene Therapy.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

With the addition of these new products, we can offer researchers more than forty different ortholog assays across six different species including monkey, dog, mouse, rat, zebrafish, and now—rabbit.

STATE COLLEGE, Pa. (PRWEB)
July 11, 2022

INDIGO Biosciences announced today the expansion of its portfolio of ortholog assays with two new progesterone receptor assays. INDIGO’s newest offerings include reporter assay systems for Cynomolgus Monkey Progesterone Receptor (NR3C3, PGR, PR) and Rabbit Progesterone Receptor (NR3C3, PGR, PR), the first rabbit ortholog assay in INDIGO’s portfolio.

“INDIGO’s cell-based assays help researchers make better decisions about a chemical’s biological activity as well as potential species differences,” said Dr. Jack Vanden Heuvel, INDIGO’s Chief Scientific Officer. “With the addition of these new products, we can offer researchers more than forty different ortholog assays across six different species including monkey, dog, mouse, rat, zebrafish, and now—rabbit.”

INDIGO’s nuclear receptor assays are particularly useful during the drug-discovery process, when researchers are evaluating compounds with the potential to become therapeutic drugs. Many of these compounds function by targeting specific nuclear receptors. Because humans and animals may share many of the same nuclear receptors, animal models are sometimes used to better understand how a compound might affect nuclear receptor activity. However, due to differences between human nuclear receptors and those of different animal models, it is important to select a model that is the most representative human surrogate.

Cell-based ortholog reporter assays are a scientific tool used to aid this decision-making process. Data from these assays can help scientists plan their research based on whether a particular animal model is predictive of a human response. Cell-based ortholog assays can also help them better understand the human relevance of data gathered from animal models. This can provide important early indications of a compound’s effectiveness, unwanted effects such as toxicity or drug-drug interactions, and therefore its potential for progressing to further development and clinical testing.

INDIGO’s cell-based ortholog reporter assays are available both as all-inclusive kits and as a screening service performed by INDIGO. To accommodate researchers’ varying needs, the kits are available in different formats including 3 x 32 and 1 x 96 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for high throughput screening applications.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor assay kits and services with greater results readability, reproducibility, and faster turnaround times. INDIGO helps researchers to reduce the time, cost, and risk associated with the discovery process through reliable science, easy-to-use products, and a highly qualified technical support team. Learn more at indigobiosciences.com.

Share article on social media or email:

WESTMINSTER, Colo. (PRWEB)
July 11, 2022

When the Aquatic Plant Management Society (APMS) holds its July 18-22 annual meeting in Greenville, S.C., members of the Weed Science Society of America (WSSA) will be on hand to present new research and best practices in weed control.

Dozens of presentations are scheduled during the event – including a special session on harmful algal blooms and how they can be best monitored and managed. Other presentations will focus on research into the biology and ecology of plants and algae in aquatic and wetland settings – from control methods for weedy invaders to restoration projects involving native species.

Examples of WSSA member participation include:

• 
  Stephen Enloe of the University of Florida will discuss various methods for removing arrowhead vine from forest wetlands.
• Erika Haug of North Carolina State University will present research on spray retention by commonly managed invasive emergent aquatic macrophytes.
• Mark Heilman of SePRO Corporation will discuss evaluations of ProcellaCOR for control of weeds and invasive aquatic plants.
• James Leary of the University of Florida will share observations on shifts in submersed aquatic vegetational communities with selective hydrilla management.
• John Madsen of the USDA’s Agricultural Research Service will discuss herbicide trials involving management of Brazilian egeria in the San Joaquin River Delta.
• Christopher Mudge of the U.S. Army Corps of Engineers will share how spray trajectory angle, pattern type and application equipment influence herbicide spray loss.
• Candice Prince of the University of Florida will share techniques for using long-term datasets to understand the impact of aquatic plant management. She will also explore the state of aquatic plant management education.
• Lee Van Wychen, executive director of science policy for WSSA and its affiliated societies, will share the results of a WSSA survey of the most common and most troublesome aquatic weeds. He will also present a Washington update on regulatory policies and budget allocations.

Other activities planned during the event include exhibits, poster sessions, an annual awards banquet, student activities and a luncheon for women in aquatic weed management. Further information on the meeting and registration details are available online.

About the Aquatic Plant Management Society

The Aquatic Plant Management Society is an international organization of scientists, educators, students, commercial pesticide applicators, administrators and concerned individuals interested in the management and study of aquatic plants. The objectives of the Society are to assist in promoting the management of nuisance aquatic plants, to provide for the scientific advancement of members of the society, to encourage scientific research, to promote university scholarship, and to extend and develop public interest in the aquatic plant science discipline. For more information, visit http://www.apms.org.

About the Weed Science Society of America

The Weed Science Society of America, a nonprofit scientific society, was founded in 1956 to encourage and promote the development of knowledge concerning weeds and their impact on the environment. The Society promotes research, education and extension outreach activities related to weeds, provides science-based information to the public and policy makers, fosters awareness of weeds and their impact on managed and natural ecosystems, and promotes cooperation among weed science organizations across the nation and around the world. For more information, visit http://www.wssa.net.

Share article on social media or email:

TORONTO, Ontario (PRWEB)
July 05, 2022

Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Visit http://www.xtalks.com to see our upcoming webinars:

BIOMARKERS

July 19- Importance of Spatial Distribution Insight from Clinical Biopsies

CLINICAL TRIALS

July 6- Commonly Overlooked Issues in CRO Selection — and How to Address Them

July 12- All Means All: The Road to Inclusivity in Clinical Trials

July 18- Decentralized and Hybrid Clinical Trials — Addressing the Complexity

COMMERCIALIZATION AND HEOR

July 20- Using Real-World Evidence on Therapy Adherence to Demonstrate Value

DRUG DISCOVERY & DEVELOPMENT

July 6- Development of Covalent Drugs with New Emerging Technologies

LABORATORY TECHNOLOGY

July 12- Alternative Approaches to Functional and Phenotypic Assays Using Multiparameter Flow Cytometry

July 13- Taking Stock: The Science Behind Modern Lab Inventory Management

July 19- Liquid Biopsy Workflow Optimization for Improved Assay Sensitivity and Multianalyte Applications of Cell-Free RNA, DNA and CTCs

July 26- Live Cell Metabolic Analysis — Paving the Way for Metabolic Research and Cell & Gene Therapy

PATIENT RECRUITMENT & RETENTION

July 21- Patient Engagement in the Digital Age: Leveraging Technology to Improve Communication Between Patients and Stakeholders

PRECLINICAL

July 19- Maintaining Safe Preservation and Traceability in Cell Culture Workflows

FOOD

July 21- Fisetin: A Little-known Nutrient that Could Lead to Breakthroughs in Longevity & Cognitive Health

July 28- Food Process Screening with an Advanced Water Reuse Filtering System to Maximize Sustainability and Savings

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://www.xtalks.com.

Share article on social media or email:

Today, spatial biology is finally giving researchers much needed contextual information resolving cells and biomarkers.

TORONTO (PRWEB)
June 30, 2022

Current immuno-oncology research is revealing diagnostic, prognostic and predictive cell states and identities with implications for drug and diagnostic development as well as diagnostic testing. However, it is challenged in that only a minority of patients respond.

This is especially prevalent using therapies that rely on immune activation such as checkpoint inhibitors, due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. The need for spatial distribution in clinical biopsies is now more than ever.

Today, spatial biology is finally giving researchers much needed contextual information resolving cells and biomarkers. It provides a comprehensive study of cellular composition, cellular functions and cell-cell interactions within the tumor microenvironment (TME).

Join this webinar to learn how spatial biology can provide insights into the spatial distribution and cellular interactions in clinical tumor biopsies.

Join Jay Lee, MD/PhD, Director of R&D and Innovation, Ultivue, for the live webinar on Tuesday, July 19, 2022, 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Importance of Spatial Distribution Insight from Clinical Biopsies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: